Ginkgo Bioworks Holdings Inc vs Wix.Com Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.71 (market cap $763.64M), while Wix.Com Ltd trades at $75.12 (market cap $3.11B). The key difference: Wix.Com Ltd is far larger — about 4.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Wix.Com Ltd for 62 Days on average.
| DNA | WIX | |
|---|---|---|
Market Cap | $763.64M | $3.11B |
Volume | 3,204,177 | 809,286 |
Sector | Health | Technology |
52-Week High | $15.83 | $145.54 |
52-Week Low | $5.48 | $40.43 |
Typical Hold Time | 7 Days | 62 Days |
Enterprise Value | $865.59M | $4.19B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Wix.com (WIX) trades at $72.97, down 1.27% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth reaching $1.99B in 2025, though net income margin remains negative at -8.19%. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing. Multiple class action lawsuits filed in September 2026 create significant legal overhang.
While analyst consensus remains bullish with 63% buy ratings and $77 price target, the combination of negative cash flow trends, legal challenges, and high valuation multiples (P/E 62.84) presents substantial risk. The stock faces headwinds from operational execution challenges despite solid revenue growth fundamentals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →